XVIPF (Xvivo Perfusion AB) Additional Paid-In Capital: $188.50 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XVIPF Xvivo Perfusion AB XVIPF
86 GF Score
Price $26.07
GF Value $43.46
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB Additional Paid-In Capital?

Xvivo Perfusion AB XVIPF 86 Additional Paid-In Capital is $188.50 Mil as of Jun. 2026. GuruFocus rates XVIPF with a GF Score™ of 86/100 and a GF Value™ of $43.46 (Significantly Undervalued). The stock has 2 warning signs investors should review.


Xvivo Perfusion AB's quarterly additional paid-in capital increased from Dec. 2025 ($192.08 Mil) to Mar. 2026 ($192.23 Mil) but then stayed the same from Mar. 2026 ($192.23 Mil) to Jun. 2026 ($188.50 Mil).

Xvivo Perfusion AB's annual additional paid-in capital declined from Dec. 2023 ($171.95 Mil) to Dec. 2024 ($161.31 Mil) but then increased from Dec. 2024 ($161.31 Mil) to Dec. 2025 ($192.08 Mil).

Xvivo Perfusion AB Additional Paid-In Capital Related Terms

Xvivo Perfusion AB Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Additional Paid-In Capital Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 137.89 126.60 171.95 161.31 192.08

Xvivo Perfusion AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 186.14 189.97 192.08 192.23 188.50
XVIPF
86GF Score
Xvivo Perfusion AB XVIPF
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $188.50 Mil mean?
Xvivo Perfusion AB (XVIPF) has a Additional Paid-In Capital of $188.50 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Additional Paid-In Capital too high?
Xvivo Perfusion AB's current Additional Paid-In Capital is $188.50 Mil. Overall, Xvivo Perfusion AB has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Additional Paid-In Capital compare to ABT and SYK?
Xvivo Perfusion AB's Additional Paid-In Capital of $188.50 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Medical Devices & Instruments company?
A good Additional Paid-In Capital depends on the Medical Devices & Instruments industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Additional Paid-In Capital is $188.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $43.46, compared to a current price of $26.07 — trading 40% below its estimated fair value. The current Additional Paid-In Capital is $188.50 Mil. Xvivo Perfusion AB's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Additional Paid-In Capital is $188.50 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of $26.07 is trading 40% below its estimated GF Value™ of $43.46. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for XVIPF:

  • Additional Paid-In Capital: $188.50 Mil
  • GF Value™: $43.46 vs. price of $26.07 (40% below fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
86GF Score

Get the complete analysis for XVIPF

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.07
Price
$43.46
GF Value